# Allied BioScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allied-bioscience

- Industry: Biotechnology
- Headquarters: Plano, US
- Website: www.alliedbioscience.com
- Latest round: Series C (May 11, 2021)
- Investors on record: 1

## About

Allied BioScience specializes in innovative antimicrobial technology to combat infectious diseases, offering long-lasting coatings that reduce viruses and bacteria on surfaces across various sectors, including healthcare and education.Founded in 2005 and headquartered in Plano, US, Allied BioScience focuses on developing advanced antimicrobial solutions. The company has undergone strategic pivots to enhance its offerings and has completed 2 deals, with the most recent deal occurring on 11 May 2021. The firm was established by Nick Dallas, who has a history of entrepreneurship in the health technology sector.Allied BioScience specializes in advanced antimicrobial technology focused on combating infectious diseases through innovative product development. Their core offerings include long-lasting antimicrobial coatings that actively reduce the presence of viruses and bacteria on surfaces, setting them apart from traditional disinfectants which only provide temporary protection. These coatings are designed for application in diverse environments such as healthcare facilities, educational institutions, and commercial spaces, aiming to create safer and healthier environments for end users, including patients, students, and employees. The company collaborates with various scientists, institutions, and industry leaders to ensure that their products are rigorously tested for consistent performance and effectiveness. Allied BioScience products are marketed across North America, Europe, and select regions in Asia, catering to a broad range of clients from hospitals to businesses seeking enhanced pathogen control.Allied BioScience generates revenue through business-to-business transactions primarily involving direct sales to various sectors, including healthcare and education. The company engages in partnerships with institutions and industry stakeholders to distribute its antimicrobial products, creating a sustainable revenue model. These transactions often involve bulk orders of their flagship antimicrobial coatings, which are utilized in ongoing maintenance and sanitation protocols. The pricing structure is designed to accommodate different client needs, with options for customizable service agreements tailored to specific sectors, ensuring long-term partnerships and repeat business. Through these strategic relationships, Allied BioScience is positioned to maintain a steady revenue stream while continuously expanding its market reach.In May 2021, Allied BioScience, Inc raised an undisclosed amount in Series C funding led by new investor Capital7. The company plans to utilize this funding for the global expansion and regulatory approval of its SurfaceWise2 product, as well as to accelerate the development of next-generation products beyond surface coatings. Allied BioScience aims to enhance its marketing efforts to drive brand awareness and increase revenues, and will also grow its employee base in North Texas to support back-end operations. The expansion plans focus on targeting new markets both domestically and internationally, with specific regions outlined for growth.

## Funding rounds

- Series C, May 11, 2021 — Capital7

## Investors

- Capital7 (https://capitalatlas.ai/funds/capital7) — Series C